title: The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
abstract: This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well-documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
authors: Departments of Laboratory Medicine and Pathology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
authors: Daniel L
authors: DL
authors: Van Dyke
authors: Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors: Lillian
authors: L
authors: Werner
authors: Moores University of California San Diego Cancer Center, La Jolla, CA, USA.
authors: Laura Z
authors: LZ
authors: Rassenti
authors: Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors: Donna
authors: D
authors: Neuberg
authors: Moores University of California San Diego Cancer Center, La Jolla, CA, USA.
authors: Emanuella
authors: E
authors: Ghia
authors: Department of Pathology, The Ohio State University, Columbus, OH, USA.
authors: Nyla A
authors: NA
authors: Heerema
authors: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors: Paola
authors: P
authors: Dal Cin
authors: Moores University of California San Diego Cancer Center, La Jolla, CA, USA.
authors: Marie
authors: M
authors: Dell Aquila
authors: North Shore-LIJ Health System, Long Island, NY, USA.
authors: Chandrika
authors: C
authors: Sreekantaiah
authors: Moores University of California San Diego Cancer Center, La Jolla, CA, USA.
authors: Andrew W
authors: AW
authors: Greaves
authors: Moores University of California San Diego Cancer Center, La Jolla, CA, USA.
authors: Thomas J
authors: TJ
authors: Kipps
authors: Departments of Laboratory Medicine and Pathology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
authors: Neil E
authors: NE
authors: Kay
mesh_terms: D002872:Chromosome Deletion; D002877:Chromosomes, Human / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D015996:Survival Rate
keywords: chronic lymphocytic leukaemia; cytogenetics; fluorescence in situ hybridization; leukaemia